News | January 28, 2023
Aarti Drugs Q3 FY23 revenue grows 4%
Standalone Q3 FY23 revenue stood at Rs. 626.5 crore as against Rs. 594.8 crore, a growth of 5% YoY
Standalone Q3 FY23 revenue stood at Rs. 626.5 crore as against Rs. 594.8 crore, a growth of 5% YoY
The issue with a face value of Rs 10 per equity share consists of a fresh issue of equity shares worth up to Rs 400 crore
The top 15 Indian pharma players have continued to experience anaemic growth in the US market over the five years ended FY22
This will give either party customers access enzyme expertise and assets, resulting in cost-effective, green processing for API manufacturing.
It ensures sufficient serum estradiol levels to alleviate menopausal symptoms
There have been reports from Uzbekistan concerning contaminated cough syrup Dok1 Max made by Indian company Marion Biotech, Noida, Uttar Pradesh
The company has plans to launch this Vaccine by the end of 2023 after completing the required field studies and obtaining regulatory approvals
As per the agreement, NSE-listed Vaishali Pharma Limited will take over the entire domestic and international marketing of Jark Pharma’s portfolio of quality based ayurvedic products
With this QIP placement, the Dhanuka group, which took over the company in 2018, is also meeting its mandatory obligation to dilute 15 percent stake in the company by March 2023
South Asia’s largest exhibition for pharma brought together over 50,000 visitors from across the globe
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
